IN8bio, Inc. announced completion of dosing of the first patient cohort in a Phase I clinical trial of INB-100, a donor-derived gamma-delta T cell therapeutic in development for patients with leukemia undergoing haploidentical stem cell transplant.
[IN8bio, Inc.]
7992332
{7992332:nan}
apa
50
1
165558
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
